{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:02:04Z","timestamp":1791597724162,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"MD Anderson Non-Standard of Care Clinical Charges","award":["Filip Janku"],"award-info":[{"award-number":["Filip Janku"]}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000371"],"award-info":[{"award-number":["UL1 TR000371"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health through MD Anderson's Cancer Center Support Grant","award":["P30-CA016672"],"award-info":[{"award-number":["P30-CA016672"]}]},{"name":"The Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy","award":["Filip Janku"],"award-info":[{"award-number":["Filip Janku"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The genomic landscape of Hodgkin lymphoma (HL) has been difficult to characterize due to the paucity of neoplastic cells and an abundant microenvironment. Such characterization is needed in order to improve treatment strategies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed comprehensive genomic profiling (CGP) using targeted next-generation sequencing on archival formalin-fixed paraffin embedded tumor samples from 63 patients to analyze the landscape of HL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CGP was successful for 49\/63 archival specimens (78%), and revealed aberrations impacting genes including B2M, TP53, and XPO1 (E571). Of the 34 patients for whom total mutation burden (TMB; mutations\/megabase [Mb]) was assessed, 5 (15%) had high TMB (\u226520 mutations\/Mb), 18 (53%) had intermediate TMB (6\u201319 mutations\/Mb), and 11 (32%) had low TMB (\u22645 mutations\/Mb). We next tested 13 patients' plasma cell-free DNA with droplet digital polymerase chain reaction for the presence of XPO1 E571 mutation, which was confirmed in the plasma of 31% of patients. In three patients with serially collected plasma samples, XPO1 E571K allelic frequency changes corresponded with changes in tumor size on conventional radiographic imaging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The study demonstrates that comprehensive genomic profiling of archival Hodgkin lymphoma tumor samples is feasible and leads to the identification of genes that are recurrently mutated and that Hodgkin lymphoma has increased mutation burden in the majority of samples analyzed. Furthermore, tracking of XPO1 E571 mutant allele frequency in a subset of patients may also represent a potential disease-monitoring strategy and warrants further investigation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This study provides the first evidence that comprehensive genomic profiling can be performed to map the genomic landscape of Hodgkin lymphoma and that a subpopulation of patients has mutations in TP53, B2M, XPO1, and other genes. It was found that 15% of patients have high mutation burden, which, in cancers such as melanoma, may indicate sensitivity to immune checkpoint inhibitors, and may thus be explored for Hodgkin lymphoma. Lastly, this work demonstrates that changes in the mutant allele frequency of XPO1 in serially collected plasma cell-free DNA samples correspond with treatment outcomes measured with conventional radiographic imaging.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0058","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T15:15:40Z","timestamp":1534259740000},"page":"219-228","source":"Crossref","is-referenced-by-count":34,"title":["Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden"],"prefix":"10.1093","volume":"24","author":[{"given":"Winnie S.","family":"Liang","sequence":"first","affiliation":[{"name":"Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Anne","family":"Vergilio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodour","family":"Salhia","sequence":"additional","affiliation":[{"name":"Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona, USA"},{"name":"Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garrido-Laguna","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeseong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fabrizio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent A.","family":"Miller","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"2021122506224700200_onco12682-bib-0001","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2011.36.1196","article-title":"PI3K\/AKT\/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations","volume":"30","author":"Janku","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122506224700200_onco12682-bib-0002","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122506224700200_onco12682-bib-0003","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122506224700200_onco12682-bib-0004","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(12)60035-X","article-title":"Hodgkin's lymphoma in adults","volume":"380","author":"Townsend","year":"2012","journal-title":"Lancet"},{"key":"2021122506224700200_onco12682-bib-0005","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood"},{"key":"2021122506224700200_onco12682-bib-0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122506224700200_onco12682-bib-0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122506224700200_onco12682-bib-0008","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2021122506224700200_onco12682-bib-0009","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"2021122506224700200_onco12682-bib-0010","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"2021122506224700200_onco12682-bib-0011","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"key":"2021122506224700200_onco12682-bib-0012","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: Exploring the world's knowledge of somatic mutations in human cancer","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2021122506224700200_onco12682-bib-0013","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/ijc.1438","article-title":"TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus","volume":"94","author":"Maggio","year":"2001","journal-title":"Int J Cancer"},{"key":"2021122506224700200_onco12682-bib-0014","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1073\/pnas.90.7.2817","article-title":"Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease","volume":"90","author":"Gupta","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122506224700200_onco12682-bib-0015","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V81.11.3097.3097","article-title":"Single-cell analysis of Hodgkin and Reed-Sternberg cells: Molecular heterogeneity of gene expression and p53 mutations","volume":"81","author":"Trumper","year":"1993","journal-title":"Blood"},{"key":"2021122506224700200_onco12682-bib-0016","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1046\/j.1365-2141.1998.00631.x","article-title":"Loss of HLA molecules in B lymphomas is associated with an aggressive clinical course","volume":"100","author":"Amiot","year":"1998","journal-title":"Br J Haematol"},{"key":"2021122506224700200_onco12682-bib-0017","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.bcp.2011.12.016","article-title":"Nuclear export of proteins and drug resistance in cancer","volume":"83","author":"Turner","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2021122506224700200_onco12682-bib-0018","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","article-title":"Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma","volume":"91","author":"Jardin","year":"2016","journal-title":"Am J Hematol"},{"key":"2021122506224700200_onco12682-bib-0019","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev"},{"key":"2021122506224700200_onco12682-bib-0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/path.2925","article-title":"PARP inhibition induces BAX\/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer","volume":"224","author":"Paul","year":"2011","journal-title":"J Pathol"},{"key":"2021122506224700200_onco12682-bib-0021","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122506224700200_onco12682-bib-0022","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1200\/JCO.2003.12.042","article-title":"TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms","volume":"21","author":"Nichols","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122506224700200_onco12682-bib-0023","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/1471-2407-12-457","article-title":"Deletion of the TNFAIP3\/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma","volume":"12","author":"Nomoto","year":"2012","journal-title":"BMC Cancer"},{"key":"2021122506224700200_onco12682-bib-0024","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J Exp Med"},{"key":"2021122506224700200_onco12682-bib-0025","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122506224700200_onco12682-bib-0026","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1182\/blood-2009-06-225839","article-title":"Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities","volume":"114","author":"Mottok","year":"2009","journal-title":"Blood"},{"key":"2021122506224700200_onco12682-bib-0027","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1038\/sj.onc.1209151","article-title":"Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation","volume":"25","author":"Weniger","year":"2006","journal-title":"Oncogene"},{"key":"2021122506224700200_onco12682-bib-0028","doi-asserted-by":"crossref","first-page":"10332","DOI":"10.1158\/0008-5472.CAN-06-1992","article-title":"Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma","volume":"66","author":"Martin-Subero","year":"2006","journal-title":"Cancer Res"},{"key":"2021122506224700200_onco12682-bib-0029","author":"Spigel","year":"2016"},{"key":"2021122506224700200_onco12682-bib-0030","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122506224700200_onco12682-bib-0031","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/219\/41917038\/oncolo_24_2_219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/2\/219\/41917038\/oncolo_24_2_219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:23:59Z","timestamp":1640413439000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/2\/219\/6439090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,8,14]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0058","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2,1]]},"published":{"date-parts":[[2018,8,14]]}}}